Portfolio company
Vedere
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops optogenetics-based gene therapies to restore vision for patients with inherited retinal dystrophies and geographic atrophy.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
Restore Vision
This clinical-stage biotechnology company develops visual restoration gene therapies to treat blindness caused by genetic retinal disorders for patients with retinitis pigmentosa.
RhyGaze
This biotechnology company develops optogenetic gene therapies to restore vision for patients with retinal diseases causing blindness.
Atsena
This clinical-stage gene therapy company develops genetic medicines to reverse or prevent blindness for patients with inherited retinal diseases.
Adverum Biotechnologies
The company develops ocular gene therapies to treat retinal diseases for patients with vision-threatening conditions such as wet age-related macular degeneration.
Beacon Therapeutics
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
Ikarovec
This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.
Sparing Vision
This genomic medicine company develops mutation-agnostic gene therapies to preserve and restore sight for patients with blinding inherited retinal diseases.